Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV.

J Int AIDS Soc 2019 Mar;22(3):e25264

Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Introduction: Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other serious bacterial infections in HIV-infected patients. Despite its in vitro activity against Mycobacterium tuberculosis, the effects of CTX preventive therapy on tuberculosis (TB) remain unclear.

Methods: Adults living with HIV enrolled in a regional observational cohort in Asia who had initiated combination antiretroviral therapy (cART) were included in the analysis. Factors associated with new TB diagnoses after cohort entry and survival after cART initiation were analysed using Cox regression, stratified by site.

Results: A total of 7355 patients from 12 countries enrolled into the cohort between 2003 and 2016 were included in the study. There were 368 reported cases of TB after cohort entry with an incidence rate of 0.99 per 100 person-years (/100 pys). Multivariate analyses adjusted for viral load (VL), CD4 count, body mass index (BMI) and cART duration showed that CTX reduced the hazard for new TB infection by 28% (HR 0.72, 95% CI l 0.56, 0.93). Mortality after cART initiation was 0.85/100 pys, with a median follow-up time of 4.63 years. Predictors of survival included age, female sex, hepatitis C co-infection, TB diagnosis, HIV VL, CD4 count and BMI.

Conclusions: CTX was associated with a reduction in the hazard for new TB infection but did not impact survival in our Asian cohort. The potential preventive effect of CTX against TB during periods of severe immunosuppression should be further explored.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jia2.25264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439318PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2019
4 Reads

Publication Analysis

Top Keywords

cart initiation
8
cd4 count
8
hazard infection
8
cohort entry
8
cohort
5
ctx
5
100 person-years /100 pys
4
099 100 person-years
4
rate 099
4
incidence rate
4
reported cases
4
cases cohort
4
entry incidence
4
/100 pys multivariate
4
adjusted viral
4
body mass
4
mass bmi
4
bmi cart
4
count body
4
load cd4
4

References

(Supplied by CrossRef)

2014
Tuberculous meningitis treatment with streptomycin, para‐aminosalicylic acid and promizole, isoniazid and streptomycin, and isoniazid
Spies HW et al.
Am Rev Tuberc 1954

Similar Publications